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Background
• Blinatumomab (blina) is a monoclonal antibody that is
•
•
•
•

used for high-risk and relapsed pediatric leukemia
patients.
Blina is administered as a 28-day continuous intravenous
infusion.
Previously, patients would remain inpatient for the entire
infusion.
To transition these patients home, local home health
agencies were contacted.
Unfortunately, no home health agencies were able care for
our pediatric patients with this investigational drug.

•
•

•

•
•

Objective

•

•

•

The goal of this quality improvement initiative was to
develop a process that would allow patients to receive at
least 21 days of their 28-day infusion at home.

Figure 2. Daily handwriting sample

A clinic nurse would visit the patient and family during their
hospitalization to complete training.
This pre-discharge education included a review of the
family resource folder, infusion pump video, demonstration
of pump operation, and a return demonstration to verify
understanding.
The pump rental company’s case manager called the
parent/guardian the first night home to address any
questions or concerns and provided a 24-hour help line to
support pump troubleshooting.
Based on hours of the outpatient clinic, patients were seen
in 72- or 96-hour increments throughout the infusion.
The patients were first seen by a provider to evaluate blina
tolerance and side effects, including a neurological exam
and review of daily handwriting samples. Handwriting
samples provide a way to monitor the patient’s CNS status
(Figure 2).
Additionally, a clinic nurse reviewed the interruption log to
ensure infusion was running appropriately.
There was coordination between interdisciplinary teams to
ensure that the patient had blina bag changes at the same
time each visit.

Figure 3. Days spent in hospital compared to days spent at home

Discussion
•

Methods

Figure 1. Family Education

•

• Rental infusion pump vendor was identified and supplied
home pumps with locking feature to prevent setting
changes.

•

• Partnership with our bi-campus outpatient hematology

•

oncology clinics, inpatient hematology oncology units,
pharmacies, and infusion pump vendor.

• Twenty-five nurse champions were identified and trained
on the equipment and supplies. These champions then
provided hands-on training to 82 additional nurses.

• Resource packets were developed to support the
inpatient/outpatient nursing teams. This included pump
troubleshooting tips, blinatumomab reference sheet,
documentation guides, and location of extra pump and
keys. This information was shared with the pediatric
emergency departments.

• Family resource folders were developed, including
education on side effects, daily handwriting samples,
basic pump troubleshooting, interruption log, when to call
provider, and calendar including bag change and labs
dates (Figures 1 & 2).

• Blina infusions were started inpatient to allow for pump
teaching prior to discharge.

Results
•
•
•
•
•
•
•

There were three patients on Children’s Oncology
Group (COG) protocol AALL1731, randomized to
the blina arm from May 2021-February 2022.
A total of 150 (out of 168) days of blina infusions
were completed outpatient utilizing the home
infusion pumps (Figure 3).
Based on an average daily inpatient cost of $3,270
per day, a total of $490,500 was saved.
A total of approximately 3,600 hours were spent in
the comfort of their home instead of the hospital.
There were three occurrences where nursing was
needed to troubleshoot the infusion – port reaccess x2, pump reset x1.
One patient experienced Grade 3 neurotoxicity,
requiring dose reduction and inpatient monitoring.
Due to close outpatient monitoring, no other
complications were noted during home infusion.

This quality improvement initiative was largely successful,
allowing us to complete blina infusions at home.
The goal of reducing inpatient days was met with this
initiative.
Patients and families anecdotally reported their satisfaction
with this infusion being managed in their home.
Ultimately this was a cost-effective initiative, freeing inpatient
beds for acutely ill patients and optimizing throughput.
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